PROFILPELAJAR.COM

Mahua Dey

Mahua Dey
Born
Dehradun, India
Known forResearch on personalized vaccines and immunotherapies for glioblastoma
Scientific career
FieldsNeurosurgery, Neuro-oncology, Cancer immunotherapy
Institutions

Mahua Dey is an American neurosurgeon and academic. She is associate professor of neurological surgery and director of the surgical neuro-oncology program at the University of Wisconsin School of Medicine and Public Health.[1][2] Her research focuses on developing immunotherapies and personalized therapeutic vaccines for malignant brain tumors, particularly glioblastoma.[3]

Early life and education

Dey grew up in Dehradun, India.[4] She earned a B.A. (Hons.) in Economics from Jadavpur University in Kolkata in 1998.[5][6] She immigrated to the United States in 1999.[6] She subsequently earned a B.S. in economics, summa cum laude, from the University of Houston in 2003 and her M.D. from Baylor College of Medicine in Houston, Texas, in 2007.[6][7][5]

Career

Dey completed her neurosurgery residency and a postdoctoral fellowship in neuro-oncology at the University of Chicago Medical Center.[7] She previously practiced as a surgical neuro-oncologist at Indiana University School of Medicine and Goodman Campbell Brain and Spine.[7]

She is board-certified in neurological surgery and specializes in the surgical management of benign and malignant brain and spinal cord tumors, including tumors in eloquent brain regions that require awake functional mapping.[1] At UW-Madison she directs the surgical neuro-oncology program while leading a translational research laboratory focused on brain tumor immunology.[2]

Research

Dey leads a translational laboratory investigating immune responses to primary and metastatic malignant brain cancers. Her work centers on developing personalized therapeutic vaccines and other immunotherapies for glioblastoma.[1][3][8]

A key project involves a personalized, gene-modified tumor vaccine (GIFT-7 fusokine approach) created from a patient's own glioblastoma cells. In preclinical mouse models, the vaccine has shown a 100% tumor response rate and induced lasting immunological memory that protects against tumor rechallenge.[1][2][8] The research is advancing toward early-phase clinical trials, including preparation of an Investigational New Drug application to the U.S. Food and Drug Administration.[2][8]

Progress toward human trials faces potential delays from federal funding uncertainties that affect NIH-supported laboratory infrastructure and regulatory processes.[2] The laboratory also develops biomarkers for real-time treatment monitoring and explores multimodal strategies that combine vaccines with standard therapies.[3]

Her publications have been cited more than 5,900 times.[9]

Awards and honors

Selected publications

  • Chang, Alan L.; Miska, Jason; Wainwright, Derek A.; Dey, Mahua; et al. (2016). "CCL2 produced by the glioma microenvironment is essential for the recruitment of regulatory T cells and myeloid-derived suppressor cells". Cancer Research. 76 (19): 5671–5682. doi:10.1158/0008-5472.CAN-16-0144. PMC 5050119. PMID 27530322.
  • Wainwright, Derek A.; Chang, Alan L.; Dey, Mahua; et al. (2014). "Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors". Clinical Cancer Research. 20 (20): 5290–5301. doi:10.1158/1078-0432.CCR-14-0514. PMID 24691018.
  • Auffinger, Brenda; Tobias, Adam L.; Han, Yu; Lee, Gina; Guo, Dongmei; Dey, Mahua; et al. (2014). "Conversion of differentiated cancer cells into cancer stem-like cells in a glioblastoma model after primary chemotherapy". Cell Death & Differentiation. 21 (7): 1119–1131. doi:10.1038/cdd.2014.31. PMC 4207480.
  • Filley, Anna C.; Henriquez, Mario; Dey, Mahua (2017). "Recurrent glioma clinical trial, CheckMate-143: the game is not over yet". Oncotarget. 8 (53): 91779–91794. doi:10.18632/oncotarget.21586. PMC 5710964.

References

  1. ^ a b c d e "Pursuing a vaccine to treat glioblastoma - A Q&A with Mahua Dey". University of Wisconsin School of Medicine and Public Health. May 14, 2025. Retrieved June 17, 2026.
  2. ^ a b c d e "UW-Madison glioblastoma vaccine research threatened by federal cuts". Wisconsin Public Radio. June 17, 2025. Retrieved June 17, 2026.
  3. ^ a b c "Meet UW-Madison's Mahua Dey". Wisconsin Alumni Research Foundation. Retrieved June 17, 2026.
  4. ^ "Mahua Dey". University of Wisconsin-Madison. Badger Talks. Retrieved June 21, 2026.
  5. ^ a b c "Mahua Dey, M.D. - K12 Neurosurgery Awardee". National Institute of Neurological Disorders and Stroke. Retrieved June 17, 2026.
  6. ^ a b c "Mahua Dey, MD - Curriculum Vitae" (PDF). Department of Neurological Surgery, University of Wisconsin School of Medicine and Public Health. March 7, 2025. Retrieved June 21, 2026.
  7. ^ a b c "Dey, Mahua - Department of Neurological Surgery". University of Wisconsin-Madison. Retrieved June 17, 2026.
  8. ^ a b c "UW Health neurosurgeon developing personalized vaccine for brain cancer". WKOW. 2025. Retrieved June 17, 2026.
  9. ^ "Mahua Dey - Google Scholar". Retrieved June 17, 2026.

Content Disclaimer

Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.

  1. The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
  2. There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
  3. It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
  4. Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
  5. Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.